MENLO PARK, Calif.–(BUSINESS WIRE)–GRAIL, Inc., a healthcare company whose mission is to detect cancer early, when it can be cured, today announced the appointment of Marissa Song as GRAIL’s General Counsel and Corporate Secretary, with responsibility for overseeing GRAIL’s legal and corporate compliance functions.
“We are very pleased to welcome Marissa, who brings extensive industry experience and a proven track record in corporate governance, SEC compliance, and product development to the role of General Counsel and Corporate Secretary,” said Hans Bishop, Chief Executive Officer at GRAIL. “In our journey to achieve something that is truly transformational, Marissa will be a great asset as we navigate critical milestones to advance our multi-cancer early detection test toward commercialization.”
Ms. Song joins GRAIL from Gilead Sciences, a research-based biopharmaceutical company where she spent more than 14 years, most recently serving as Vice President of Corporate Legal. There, she led the corporate governance and SEC reporting group as well as the teams supporting finance, human resources, privacy and information governance, product development and manufacturing, global facilities, and clinical trials. Prior to joining Gilead, Ms. Song was a Corporate Associate at Latham & Watkins LLP, focusing on mergers and acquisitions. She currently serves on the Board of the Disability Rights Legal Center. Ms. Song earned her bachelor’s degree from the University of California, Berkeley and her JD from the University of Southern California.
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is located in Menlo Park, California. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. For more information, please visit www.grail.com.